Suppr超能文献

慢性髓系白血病:细胞遗传学方法及其在诊断和治疗中的应用

Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment.

作者信息

Morris Christine M

机构信息

Cancer Genetics Research Group, Department of Pathology, University of Otago Christchurch School of Medicine and Health Services, Christchurch, New Zealand.

出版信息

Methods Mol Biol. 2011;730:33-61. doi: 10.1007/978-1-61779-074-4_4.

Abstract

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease caused by recombination between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. This rearrangement generates the BCR-ABL1 fusion gene that characterizes leukemic cells in all CML cases. In about 90% of cases, the BCR-ABL1 rearrangement is manifest cytogenetically by the Philadelphia (Ph) chromosome, a derivative of the reciprocal translocation t(9;22)(q34;q11.2). For the remaining cases, recombination may be more complex, involving BCR, ABL1, and genomic sites on one or more other chromosomal regions, or it may occur cryptically within an apparently normal karyotype. Detection of the Ph and associated t(9;22) translocation is a recognized clinical hallmark for CML diagnosis. The disease has a natural multistep pathogenesis, and during chronic phase CML, the t(9;22) or complex variant is usually the sole abnormality. In 60-80% of cases, additional cytogenetic changes appear and often forecast progression to an accelerated disease phase or a terminal blast crisis. Because new frontline therapies such as imatinib specifically target the abnormal protein product of the BCR-ABL1 fusion gene to eliminate BCR-ABL1 positive cells, there is a new reliance on the cytogenetic evaluation of bone marrow cells at diagnosis, then at regular posttreatment intervals. Combined with other parameters, presence or absence of Ph-positive cells in the bone marrow is a powerful early indicator for clinical risk stratification. Cytogenetic changes detected at any stage during treatment, including in the BCR-ABL1-negative cells, may also provide useful prognostic information. Laboratory methods detailed here extend from initial collection of peripheral blood or bone marrow samples through cell culture with or without synchronization, metaphase or interphase harvest, hypotonic treatment and fixation, slide preparation for G-banding or fluorescent in situ hybridization (FISH), and final interpretation.

摘要

慢性髓性白血病(CML)是一种克隆性骨髓增殖性疾病,由22号染色体上的BCR基因与9号染色体上的ABL1基因重组引起。这种重排产生了BCR-ABL1融合基因,该基因是所有CML病例中白血病细胞的特征。在约90%的病例中,BCR-ABL1重排在细胞遗传学上表现为费城(Ph)染色体,即相互易位t(9;22)(q34;q11.2)的衍生染色体。对于其余病例,重组可能更为复杂,涉及BCR、ABL1以及一个或多个其他染色体区域上的基因组位点,或者可能在看似正常的核型内隐匿发生。检测Ph染色体及相关的t(9;22)易位是CML诊断公认的临床标志。该疾病具有自然的多步骤发病机制,在慢性期CML中,t(9;22)或复杂变异通常是唯一的异常。在60 - 80%的病例中,会出现其他细胞遗传学改变,且常常预示着疾病进展至加速期或终末期急变期。由于伊马替尼等新的一线治疗方法特异性靶向BCR-ABL1融合基因的异常蛋白产物以消除BCR-ABL1阳性细胞,因此在诊断时以及治疗后的定期间隔,对骨髓细胞进行细胞遗传学评估有了新的依赖。结合其他参数,骨髓中Ph阳性细胞的有无是临床风险分层的有力早期指标。治疗期间任何阶段检测到的细胞遗传学改变,包括BCR-ABL1阴性细胞中的改变,也可能提供有用的预后信息。这里详细介绍的实验室方法从外周血或骨髓样本的初始采集开始,经过有或无同步化的细胞培养、中期或间期收获、低渗处理和固定、用于G显带或荧光原位杂交(FISH)的玻片制备,直至最终解读。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验